 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
7 News |  |
- ||| ISIS-EIF4ERx / Ionis
Trial completion, Phase classification, Combination therapy, Metastases: Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (clinicaltrials.gov) - Jun 27, 2018
P1b/2, N=116, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2
- ||| ISIS-EIF4ERx / Ionis
Trial completion, Phase classification, Combination therapy: Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) (clinicaltrials.gov) - Jun 27, 2018
P1b/2, N=113, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2 Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2
- ISIS-EIF4ERx / Ionis
Enrollment closed, Enrollment change, Combination therapy, Metastases: ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) - Oct 23, 2014
P1/2, N=20, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2 Recruiting --> Active, not recruiting | N=45 --> 20
- ISIS-EIF4ERx / Ionis
Trial primary completion date, Combination therapy, Metastases: ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) - Jun 24, 2014
P1/2, N=45, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=45 --> 20 Trial primary completion date: Jul 2014 --> Dec 2014
- ||| ISIS-EIF4ERx / Ionis
Enrollment closed, Combination therapy, Metastases: Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (clinicaltrials.gov) - Oct 31, 2012
P1/2, N=112, Active, not recruiting, Sponsor: Isis Pharmaceuticals
Trial primary completion date: Jul 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- ||| ISIS-EIF4ERx / Ionis
Enrollment closed, Combination therapy: Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) (clinicaltrials.gov) - Oct 31, 2012
P1/2, N=112, Active, not recruiting, Sponsor: Isis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ISIS-EIF4ERx / Ionis
New P1/2 trial, Combination therapy, Metastases: ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=45, Recruiting, Sponsor: National Cancer Institute (NCI)